Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
PRAME family member 11 (PRAMEF11) is a protein-coding gene on chromosome 1 (12,824,605–12,831,410, reverse strand), encoding a protein predicted to enable ubiquitin-like ligase-substrate adaptor activity and to participate in proteasome-mediated, ubiquitin-dependent protein catabolic processes as part of a Cullin-2 RING ubiquitin ligase complex[1][9][10]. It is one of the PRAME (Preferentially Expressed Antigen in Melanoma) family members, potentially sharing some characteristics with the broader PRAME family, such as leucine-rich repeats and possible involvement in nuclear receptor signaling, but specific direct biological or therapeutic functions for PRAMEF11 remain unvalidated in the current literature[1][9][10]. There are no known interacting drugs, established biomarkers, or safety concerns documented for PRAMEF11, and it is not currently considered an established therapeutic target.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on PRAME family member 11 (PRAMEF11).